pharma · Symptomatic hypertrophic cardiomyopathy (HCM) · SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Cytokinetics
Cytokinetics (Ireland) Limited
Cytokinetics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 1998
- Employees
- 759
- Programs
- 5
- Drugs
- 7
- Patents
- 0
Cytokinetics projects
4 ClinicalTrials.gov programs sponsored by Cytokinetics.
Cytokinetics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CY 1033
Cytokinetics (Ireland) Limited
Heart Failure With Reduced Ejection Fraction
1 trial -
CY 6023
Cytokinetics (Ireland) Limited
SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
1 trial -
CY 6032
Cytokinetics (Ireland) Limited
Symptomatic Obstructive Hypertrophic Cardiomyopathy
1 trial -
CY 6033
Cytokinetics (Ireland) Limited
SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
1 trial
Frequently asked questions
How many clinical projects does Cytokinetics have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.